Avalo Therapeutics Inc.
AVTX | NASDAQ
$16.52
+$0.35 (+2.16%)
Sep 22, 2026, 12:30 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -3.11 | -1.72 | -0.08 | -1.14 | -2.10 | -3.01 |
PEG Ratio | -0.09 | 0.02 | 0 | 0.02 | 0.27 | -0.01 |
PS Ratio | 4.13K | 136.95 | 1.31 | 2.63 | 32.83 | 28.95 |
PB Ratio | 2.93 | 0.45 | 0.35 | -4.34 | 7.68 | 7.90 |
P/FCF Ratio | -4.73 | -1.23 | -0.08 | -1.77 | -2.50 | -4.78 |
P/OCF Ratio | -4.73 | -1.23 | -0.08 | -1.77 | -2.50 | -4.78 |
OCF/S Ratio | -87.22K | -11.12K | -1.59K | -148.20 | -1.31K | -605.15 |
Debt / Equity Ratio | 0.03 | 0 | 0.07 | -1.83 | 1.44 | 0.02 |
Quick Ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 | 1.71 |
Current Ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 | 1.71 |
Asset Turnover | 0 | 0 | 0.09 | 0.54 | 0.07 | 0.15 |
Interest Coverage | n/a | n/a | -8 | -8.98 | -34.35 | n/a |
Return on Equity | -94.23% | -26.41% | -431.87% | 381.66% | -365.55% | -258.53% |
Return on Assets | -67.20% | -23.31% | -150.26% | -124.85% | -105.19% | -145.13% |
Return on Invested Capital | -70.18% | -47.47% | -161.73% | -211.35% | -134.75% | n/a |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 100% | 182.99% | 33.26% | 80.98% | 72.38% | 95.52% |
Net Profit Margin | -132.64K% | -7.97K% | -1.64K% | -230.78% | -1.56K% | -947.90% |
Pretax Profit Margin | -132.36K% | -7.94K% | -1.64K% | -230.62% | -1.57K% | -1K% |
Operating Profit Margin | -123.6K% | -15.54K% | -1.42K% | -207.41% | -1.52K% | n/a |
FCF Margin | -87.22K% | -11.12K% | -1.6K% | -148.72% | -1.32K% | -606.09% |
EBITDA Margin | -131.78K% | -7.9K% | -1.21K% | -206.60% | -1.49K% | -678.47% |
Add to Watchlist
Select watchlists to add or remove AVTX